Perma-Pipe International Holdings, Inc. (NASDAQ: PPIH) today announced that it secured $52 million in project awards during the third quarter of 2025, including $30 million previously announced in September. The additional $22 million in new awards includes major data center infrastructure projects in the United States and Saudi Aramco–related projects to be executed from the company’s recently approved Dammam, Saudi Arabia facility. “These awards underscore the accelerating demand we’re seein...
Celltrion, Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion of autoinjector of SteQeyma™, a biosimilar to Stelara® (ustekinumab), for the treatment of plaque psoriasis, psoriatic arthritis (PsA) and Crohn’s disease (CD). The positive CHMP opinion is for SteQeyma autoinjector in 45mg/0.5mL and 90mg/1mL, expanding the currently approved SteQeyma™ presentation, which includes 45mg/0.5mL, 90mg/...
Kioxia Corporation today announced that its 2.5-inch KIOXIA CM7 Series Enterprise PCIe® 5.0 NVMe™ 2.0, KIOXIA CD8P Series Data Center PCIe 5.0 NVMe 2.0 and KIOXIA CD8 Series Data Center PCIe 4.0 NVMe 1.4 SSDs have been successfully tested for compatibility and interoperability with the Adaptec® SmartRAID 4300 Series RAID storage accelerator card from Microchip Technology Inc. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/2025121746108...
RHI Magnesita, the leading global supplier of high-grade refractory products, systems, and solutions, has strengthened its operations in the Middle East, Türkiye, and Africa (META) region by setting up a new business unit headquartered in Dubai with ambitions to propel further growth and expansion in the region. The company inaugurated its new regional office yesterday, marking a key milestone in its growth journey and underscoring a long-term commitment to customers across the region. This pre...
Pattern Group Inc. (Nasdaq: PTRN), a leader in accelerating brands on global ecommerce marketplaces by leveraging proprietary technology and AI, today announced that it has acquired ROI Hunter a.s., a performance-driven retail media platform for brands and retailers. ROI Hunter integrates product, marketing, and merchandising data into a single source of truth, enabling margin-informed, SKU-level advertising decisions across major walled-garden platforms including Google, Meta, and Snap. The a...
Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™, and the leading third-party support provider for Oracle, SAP and VMware software, today introduced Rimini Agentic UX™, an intelligent, AI-driven user engagement layer that streamlines ERP process execution for efficiency and significant savings, delivering persona- and role-based automation and productivity enhancements without the need for costly ERP Software upgrades or migrations. This press release feature...
Global Critical Logistics (GCL) announced today its brand evolution into the newly unveiled identity of The Rock-It Company, uniting its diverse portfolio under the iconic and globally recognized name. The announcement arrives as Rock-It delivers some of the world’s most impactful cultural moments this week including the Final Draw of the FIFA World Cup 2026™ in Washington D.C., Art Basel in Miami, The Conference at Rock Lititz and several concerts and automotive events in Abu Dhabi, including ...
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with r...
The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for DATROWAY® (datopotamab deruxtecan) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. DATROWAY is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and com...